Marisa Wexler, MS,  senior science writer—

Treatment with Trikafta (ivacaftor/tezacaftor/elexacaftor) may help to ease a particular type of lung inflammation found in people with cystic fibrosis (CF), called a type 2 inflammatory response, that’s often associated with asthma and allergies. As asthma is reported to affect 30.8% of CF patients, a research team wondered…

New grants awarded by the Cystic Fibrosis Foundation will help fund 10 programs that support people impacted by cystic fibrosis (CF). The awards are being given through the foundation’s eighth annual Impact Grants, which provide as much as $10,000 for up to two years to people and nonprofit…

Scientists have synthesized a new compound that can boost the activity of the CFTR protein carrying the most common mutation that causes cystic fibrosis (CF). In cell models, the compound was able to further increase the activity of approved CFTR modulators. The compound’s development was described in the…

Treatment with the CFTR modulator Kalydeco (ivacaftor) led to significant weight gain, suggesting better nutritional status, in  babies and toddlers with cystic fibrosis (CF) eligible for this therapy’s use, a study reports. “Young children experienced favorable changes in weight gain and some nutritional biomarkers in the first 12…

Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) can improve lung function and nutritional status for people with cystic fibrosis (CF) caused by the N1303K mutation, a small real-world study reports. The N1303K mutation is not among the 178 disease-causing mutations in the CFTR gene considered to be responsive to Trikafta and…

Researchers have synthesized two new molecules that are able to kill Staphylococcus aureus and Pseudomonas aeruginosa — two species of bacteria that commonly cause lung infections in people with cystic fibrosis (CF). These new molecules, known as synthetic nano-engineered antimicrobial polymers or SNAPs, showed synergistic bacteria-killing effects when combined with…

Dosing has begun in a Phase 1 clinical trial of CM001, an inhaled treatment designed to act as a molecular prosthetic in cells and treat cystic fibrosis (CF) regardless of a patient’s underlying mutation, Cystetic Medicines, the therapy’s developer, announced. Most immediately, the company expects that CM001…

In the months after starting on Trikafta, people with cystic fibrosis (CF) generally experience lower rates of hospitalizations and lung infections — but nonetheless, the total cost of healthcare for these patients tends to increase, a new economic analysis indicates. The findings are in line with prior analyses…

Top-line results are expected next month for the SPAN clinical trial, a Phase 2 study testing First Wave BioPharma‘s new formulation of adrulipase to treat exocrine pancreatic insufficiency (EPI) in people with cystic fibrosis (CF). The trial’s target enrollment has been reached, with 13 total participants signed on,…

Long-term treatment with Trikafta leads to sustained improvements in lung function, easing of respiratory symptoms, and better nutritional status for people with cystic fibrosis (CF) who have at least one copy of the F508del mutation. That’s according to new data presented by the therapy’s developer Vertex Pharmaceuticals…